Omics · study · 2026
Neoadjuvant Palbociclib Treatment Impacts Cell Cycle Progression of DCIS
Listed in NCBI GEO
Background.
Description
Ductal carcinoma in situ (DCIS) is a non-invasive disease of the breast. This study assessed the impact of the CDK4/6 inhibitor, Palbociclib, on halting cell cycle progression of DCIS between diagnostic biopsy and surgical resection of the lesion.
Methods. A dual-arm study was conducted involving 15 patients with DCIS who were given either 100mg palbociclib PO daily for twelve days or no treatment before surgery. FFPE tissues from the diagnostic biopsy and from surgical specimens were analyzed to assess changes due to treatment.
Read the rest (4 more)
Results. Palbociclib treatment significantly reduced Ki67 staining in surgical tissues. Also, RNA-seq analysis comparing the diagnostic biopsy and surgical specimens showed significant downregulation of cellular proliferation pathways after treatment.
A cellular deconvolution analysis revealed a treatment-induced decrease in the abundance of mature luminal epithelial cells. Conclusion. We found that short-term treatment with palbociclib before surgical resection was safe and well tolerated in patients.
Tissue analysis showed a significant reduction in proliferation markers and downregulation of cell cycle progression genes within DCIS. These results indicate that palbociclib may be effective in the neoadjuvant setting of early stage breast cancer. Trial registration.
ClinicalTrials.gov NCT03535506
Links
Get the data
- GEO FTP directory ftp.ncbi.nlm.nih.gov/geo/series/GSE324nnn/GSE324721 ↗
download · from NCBI GEO
Where it is published
- GEO accession page ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE324721 ↗
landing page · from NCBI GEO
Documentation and papers
- PRJNA1436853 ncbi.nlm.nih.gov/bioproject/PRJNA1436853 ↗
project · from NCBI GEO
- PubMed 42649946 pubmed.ncbi.nlm.nih.gov/42649946 ↗
publication · from NCBI GEO
Topics
- Stated by source
- Expression profiling by high throughput sequencing · Homo sapiens
- From keywords
- Life Sciences
- Inferred from text
- Cancer 75% · Disease 75% · RNA sequencing 65%
Provenance · 1 source records, 10 field assertions
| Source | Key | Last seen | Raw |
|---|---|---|---|
| NCBI GEO | GSE324721 | 15 d ago | JSON v1 |
| Field | Assertion | Extractor | Evidence |
|---|---|---|---|
| access_level | source · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| concepts[disease].local:disease:cancer | enrichment · NCBI GEO | keyword-concept-rules@1.0.0 | title+description (75%) |
| concepts[disease].local:disease:disease | enrichment · NCBI GEO | keyword-concept-rules@1.0.0 | title+description (75%) |
| concepts[field].local:field:life-sciences | mapping · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| concepts[method].geo_series_type:expression-profiling-by-high-throughput-sequencing | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /gdstype |
| concepts[modality].local:modality:rna-seq | enrichment · NCBI GEO | keyword-concept-rules@1.0.0 | title+description (65%) |
| concepts[organism].NCBITaxon:9606 | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /taxon |
| description | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /summary |
| publication_date | source · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| title | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /title |